Zydus Lifesciences Launches AI-Powered Glucose Monitoring Devices Diasens and GlucoLive

Zydus Lifesciences Ltd has launched two next-generation Continuous Glucose Monitoring (CGM) devices, Diasens and GlucoLive, to expand its companion diagnostics portfolio.

These devices combine artificial intelligence, real-time glucose monitoring, and remote care features to help patients and doctors track blood sugar levels more effectively.

The launch was announced in Ahmedabad on March 12, 2026.

Designed for Chronic Disease Patients

The new CGM devices are designed mainly for patients who require continuous monitoring of blood sugar levels, including those with:

• Diabetes
• Chronic Kidney Disease
• Patients who have undergone organ transplants

These patients often need constant monitoring to manage their health and avoid complications.

Partnership with TatvaCare for Digital Healthcare

To support the new system, Zydus has partnered with Digicare Health Solutions Private Limited (TatvaCare).

The devices are connected to the GoodFlip App, a digital health platform that provides:

• AI-based report analysis
• Personalised diet and exercise guidance
• Doctor consultations
• Diagnostic lab booking
• Secure storage of medical records

This integrated system helps create a connected care ecosystem for patients, doctors, and caregivers.

Real-Time Glucose Monitoring with AI Insights

Unlike many existing CGM devices in India that require manual scanning, Diasens and GlucoLive automatically send glucose readings to the patient’s smartphone every three minutes.

This ensures continuous monitoring, including overnight tracking and emergency alerts.

The AI-powered system can:

• Detect unusual glucose trends
• Identify low or high blood sugar episodes
• Link glucose changes with food and activity
• Provide useful health insights for better disease management

Doctors can also access a remote monitoring dashboard, allowing them to adjust treatment based on real-time patient data.

Rising Diabetes Burden in India

India currently has over 101 million adults living with diabetes, making it one of the countries with the highest number of cases globally.

Another 136 million people are in the pre-diabetic stage, according to studies published in The Lancet Diabetes & Endocrinology.

Diabetes is also a leading cause of kidney disease, with around 25–40% of patients with Chronic Kidney Disease having a history of diabetes.

Strengthening Zydus’ Healthcare Innovation

The launch reflects the company’s focus on combining science, technology, and healthcare innovation to improve disease management.

Sharvil Patel, Managing Director of Zydus Lifesciences Ltd, said the devices aim to provide simple, reliable, and convenient glucose monitoring solutions for patients managing chronic diseases.

Read More:Adani Enterprises Share Price in Focus; Incorporates Wholly Owned Subsidiary CORR Tollways Limited!

Zydus Lifesciences Share Price Movement

Zydus Lifesciences share price (NSE: ZYDUSLIFE) closed at ₹915.65 on March 12, falling ₹6.10 or 0.66% for the day. The stock opened at ₹918.50 and moved between an intraday high of ₹926.60 and a low of ₹909.50. The company currently has a market capitalisation of ₹92.14 lakh crore and trades at a price-to-earnings (P/E) ratio of 18.65. 

Conclusion

With the launch of Diasens and GlucoLive, Zydus Lifesciences Ltd is strengthening its presence in digital healthcare and companion diagnostics. By combining AI, real-time monitoring, and remote medical support, the company aims to help patients manage chronic diseases more effectively and improve overall healthcare outcomes.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.